Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers
Data were taken from a prospective, multi-center, observational study (NCT02889978), which evaluated cell-free DNA multi-omics in prototype cfDNA-based multi-cancer early detection tests. In the study, researchers collected plasma and matched white blood cells before sequencing them from CCGA study participants (n = 2,800). Tumor biopsies were also sequenced when available….
cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection
Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection. Clinical limit of detection (cLOD) may be a reasonable metric for evaluating cell-free DNA (cfDNA) for multi-cancer early detection, according to recent data from the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978). In…